Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

NeuroSearch (Huntexil)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Neuro control drug to treat patients from Huntington disease. The drug is used as a symptomatic agent, and enables the patients to get rid of the irregularities of their hand movement, balance and gait disturbances caused due to the Huntington disease.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Acquirer
Teva Pharmaceutical Industries
Primary Office
  • Strandvejen 60
  • 2900 Hellerup
  • Denmark

NeuroSearch (Huntexil) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore NeuroSearch (Huntexil)‘s full profile, request access.

Request full access to PitchBook

NeuroSearch (Huntexil) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore NeuroSearch (Huntexil)‘s full profile, request access.

Request full access to PitchBook